US Supplement Firm Warnings Up, Enforcement Tools Idle, Hemp and NAC Still In Limbo
Executive Summary
FDA “didn’t really take any steps towards a resolution” in 2021 and is “mostly content” with enforcement discretion allowing sales of non-drug products which contain cannabinoids and other hemp-derive ingredients, says Stuart Pape, of Polsinelli PC, during a recent Food and Drug Law Institute conference.
You may also be interested in...
Honey Nasal Spray Recall Plus FDA Investigation Adds Up To California Firm Closing Up Shop
FDA inspection seven months after NDAL Manufacturing announced recall of Manukaguard Allercleanse nasal spray with manuka honey found firm’s compliance with GMP regulations left room for contaminants to reach its products. Violative drug claims and mislabeled supplements also found.
US Cannabis Legalization Cultivated By House Has Thorny Forecast For Harvest In Senate
Absence of hemp provisions in House bill could be a problem with Senate Democrats, who have drafted legislation not only on producing, marketing and possessing marijuana but also using in supplements ingredients classified as hemp. Still, Senate passage of cannabis legalization is unlikely.
NAC Gains Tentative Safety Clearance As US Industry Contests FDA's Attempt To Remove It
FDA answers reach supplement industry sounding like a siren that the agency may take same enforcement step it has with NAC with other ingredients long used in supplements. Answers also might not be enough to convince firms to return NAC-containing supplements to their lineups.